Moxifloxacin Injection — FDA Drug Shortage

To Be Discontinued — Fresenius Kabi USA, LLC

The FDA lists a drug shortage record for Moxifloxacin Injection (injection) from Fresenius Kabi USA, LLC with status To Be Discontinued. The shortage was first posted on 10/29/2025.

Shortage Details

Status
To Be Discontinued
Company
Fresenius Kabi USA, LLC
Package NDC
63323-850-74
Dosage Form
Injection
Presentation
Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74)
Initial Posting
10/29/2025
Revised Date